FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2029682365> ?p ?o ?g. }

• W2029682365 endingPage "4058" @default.
• W2029682365 startingPage "4047" @default.
• W2029682365 abstract "Abstract Purpose: PI3K–Akt is overexpressed in 50% to 70% of pancreatic ductal adenocarcinoma (PDAC). The hypothesis of this study is that PI3K and EGFR coinhibition may be effective in PDAC with upregulated PI3K–Akt signaling. Experimental Design: Multiple inhibitors were tested on five PDAC cell lines. EGFR inhibitor (EGFRi)–resistant cell lines were found to have significantly overexpressed AKT2 gene, total Akt, and pAkt. In vitro erlotinib-resistant (ER) cell models (BxPC-ER and PANC-ER) with highly constitutively active PI3K–Akt were developed. These and their respective parent cell lines were tested for sensitivity to erlotinib, IGFIR inhibitor NVP-AEW541 (AEW), and PI3K-alpha inhibitor NVP-BYL719 (BYL), alone or in combination, by RTK-phosphoarray, Western blotting, immunofluorescence, qRT-PCR, cell proliferation, cell cycle, clonogenic, apoptosis, and migration assays. Erlotinib plus BYL was tested in vivo. Results: Erlotinib acted synergistically with BYL in BxPC-ER (synergy index, SI = 1.71) and PANC-ER (SI = 1.44). Treatment of ER cell lines showing upregulated PI3K–Akt with erlotinib plus BYL caused significant G1 cell-cycle arrest (71%, P &lt; 0.001; 58%, P = 0.003), inhibition of colony formation (69% and 72%, both P &lt; 0.001), and necrosis and apoptosis (75% and 53%, both P &lt; 0.001), more so compared with parent cell lines. In primary patient-derived tumor subrenal capsule (n = 90) and subcutaneous (n = 22) xenografts, erlotinib plus BYL significantly reduced tumor volume (P = 0.005). Strong pEGFR and pAkt immunostaining (2+/3+) was correlated with high and low responses, respectively, to both erlotinib and erlotinib plus BYL. Conclusion: PDAC with increased expression of the PI3K–Akt pathway was susceptible to PI3K–EGFR coinhibition, suggesting oncogenic dependence. Erlotinib plus BYL should be considered for a clinical study in PDAC; further evaluation of pEGFR and pAkt expression as potential positive and negative predictive biomarkers is warranted. Clin Cancer Res; 20(15); 4047–58. ©2014 AACR." @default.
• W2029682365 created "2016-06-24" @default.
• W2029682365 creator A5014740620 @default.
• W2029682365 creator A5019162069 @default.
• W2029682365 creator A5025294735 @default.
• W2029682365 creator A5032567530 @default.
• W2029682365 creator A5034795863 @default.
• W2029682365 creator A5044901015 @default.
• W2029682365 creator A5057619248 @default.
• W2029682365 creator A5075497936 @default.
• W2029682365 creator A5080031908 @default.
• W2029682365 creator A5085372050 @default.
• W2029682365 date "2014-07-31" @default.
• W2029682365 modified "2023-10-11" @default.
• W2029682365 title "Cotargeting of Epidermal Growth Factor Receptor and PI3K Overcomes PI3K–Akt Oncogenic Dependence in Pancreatic Ductal Adenocarcinoma" @default.
• W2029682365 cites W118828521 @default.
• W2029682365 cites W1585504346 @default.
• W2029682365 cites W1931508686 @default.
• W2029682365 cites W1972486056 @default.
• W2029682365 cites W1973890143 @default.
• W2029682365 cites W1981824665 @default.
• W2029682365 cites W1998836974 @default.
• W2029682365 cites W2016276144 @default.
• W2029682365 cites W2019607817 @default.
• W2029682365 cites W2021963511 @default.
• W2029682365 cites W2035126411 @default.
• W2029682365 cites W2043103956 @default.
• W2029682365 cites W2044548139 @default.
• W2029682365 cites W2050747125 @default.
• W2029682365 cites W2053439872 @default.
• W2029682365 cites W2055174648 @default.
• W2029682365 cites W2083728982 @default.
• W2029682365 cites W2086191517 @default.
• W2029682365 cites W2087617431 @default.
• W2029682365 cites W2096491402 @default.
• W2029682365 cites W2103894337 @default.
• W2029682365 cites W2113837682 @default.
• W2029682365 cites W2114414968 @default.
• W2029682365 cites W2129056290 @default.
• W2029682365 cites W2140228520 @default.
• W2029682365 cites W2144025124 @default.
• W2029682365 cites W2148168351 @default.
• W2029682365 cites W2150026213 @default.
• W2029682365 cites W2151253787 @default.
• W2029682365 cites W2154790710 @default.
• W2029682365 cites W2155127143 @default.
• W2029682365 cites W2158134441 @default.
• W2029682365 cites W2161884651 @default.
• W2029682365 cites W2172206677 @default.
• W2029682365 cites W4251192558 @default.
• W2029682365 doi "https://doi.org/10.1158/1078-0432.ccr-13-3377" @default.
• W2029682365 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24895459" @default.
• W2029682365 hasPublicationYear "2014" @default.
• W2029682365 type Work @default.
• W2029682365 sameAs 2029682365 @default.
• W2029682365 citedByCount "32" @default.
• W2029682365 countsByYear W20296823652014 @default.
• W2029682365 countsByYear W20296823652015 @default.
• W2029682365 countsByYear W20296823652016 @default.
• W2029682365 countsByYear W20296823652017 @default.
• W2029682365 countsByYear W20296823652018 @default.
• W2029682365 countsByYear W20296823652019 @default.
• W2029682365 countsByYear W20296823652020 @default.
• W2029682365 countsByYear W20296823652021 @default.
• W2029682365 countsByYear W20296823652022 @default.
• W2029682365 countsByYear W20296823652023 @default.
• W2029682365 crossrefType "journal-article" @default.
• W2029682365 hasAuthorship W2029682365A5014740620 @default.
• W2029682365 hasAuthorship W2029682365A5019162069 @default.
• W2029682365 hasAuthorship W2029682365A5025294735 @default.
• W2029682365 hasAuthorship W2029682365A5032567530 @default.
• W2029682365 hasAuthorship W2029682365A5034795863 @default.
• W2029682365 hasAuthorship W2029682365A5044901015 @default.
• W2029682365 hasAuthorship W2029682365A5057619248 @default.
• W2029682365 hasAuthorship W2029682365A5075497936 @default.
• W2029682365 hasAuthorship W2029682365A5080031908 @default.
• W2029682365 hasAuthorship W2029682365A5085372050 @default.
• W2029682365 hasBestOaLocation W20296823651 @default.
• W2029682365 hasConcept C117262875 @default.
• W2029682365 hasConcept C121608353 @default.
• W2029682365 hasConcept C126322002 @default.
• W2029682365 hasConcept C185592680 @default.
• W2029682365 hasConcept C190283241 @default.
• W2029682365 hasConcept C2778087573 @default.
• W2029682365 hasConcept C2779438470 @default.
• W2029682365 hasConcept C29537977 @default.
• W2029682365 hasConcept C502942594 @default.
• W2029682365 hasConcept C55493867 @default.
• W2029682365 hasConcept C62112901 @default.
• W2029682365 hasConcept C71924100 @default.
• W2029682365 hasConcept C75217442 @default.
• W2029682365 hasConcept C86554907 @default.
• W2029682365 hasConceptScore W2029682365C117262875 @default.
• W2029682365 hasConceptScore W2029682365C121608353 @default.
• W2029682365 hasConceptScore W2029682365C126322002 @default.
• W2029682365 hasConceptScore W2029682365C185592680 @default.
• W2029682365 hasConceptScore W2029682365C190283241 @default.
• W2029682365 hasConceptScore W2029682365C2778087573 @default.

• next